Want to join the conversation?
World's leading healthcare diagnostics provider $LH launched a new FDA-approved diagnostic test for PD-L1 with expanded approval of $BMY's OPDIVO (nivolumab) treating patients with previously-treated non-small cell lung cancer (NSCLC). $LH's CEO quoted "The launch of this innovative assay reinforces the importance of LabCorp-Covance combination."
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.